002940.SZ
昂利康
SZSE · Healthcare · C 制造业 · CN
CNY 25.29
−4.17%Aug 24, 2026, 09:33 UTC
Anglikang announced its 2026 first-half results: net profit attributable to shareholders was 54.9264 million yuan, down 16.68% year-on-year.
Source:Aug 2, 2026, 08:11 UTC
Anglikang and its subsidiary HaiXi Pharmaceutical's three drugs are provisionally selected in the 12th national centralized drug procurement, with the procurement period lasting until December 31, 2029.
Source:Jul 24, 2026, 08:59 UTC
Anglikang received a Drug Registration Certificate for Loxoprofen Sodium Gel Patch, used for anti-inflammatory and analgesic treatment of osteoarthritis and other diseases.
Source: